Summary
• PDS Biotechnology Corporation (PDSB) gained 12.9% in pre-market, reaching $0.8099.
• Analyst Kalpit Patel of B. Riley Securities maintained a “Buy” rating with a price target of $3 to $5.
• Technical indicators show mixed performance, with the stock below short-term averages and a current RSI of 35.4.
PDS Biotechnology Corporation (PDSB) saw a significant gain in the pre-market session, rising to $0.8099, up 12.9% from its previous close of $0.7177. The stock has moved without a clear catalyst, reflecting the ongoing trading dynamics in the biotechnology sector.
Analyst Sentiment Underpins Positive Movement
The stock’s upward momentum may align with the latest analyst sentiment, as Kalpit Patel from B. Riley Securities maintained a “Buy” rating on November 25, 2025, with a price target range of $3 to $5. This maintained confidence could be contributing to today’s pre-market gains, despite a recent earnings report that fell slightly short of expectations, showing a current actual EPS of -$0.19 against an estimate of -$0.21.
Market and Technical Picture
Looking at the technical analysis, PDSB exhibits a mixed performance backdrop. The stock is currently below its short-term average (SMA20 at -14.8%) and mid-term average (SMA50 at -22.4%), while showing a dramatic yearly underperformance of -71.8%. With a recent average volume over the past 10 days of 384,329 shares, trading volume seems to fluctuate significantly compared to the average of 724,017 shares over the last three months. The current RSI is at 35.4, indicating that the stock is on the cusp of potentially oversold territory, which may elicit further interest from investors.
Closing Thoughts
With the stock reacting positively in pre-market trading, investors appear to be considering the favorable analyst outlook despite routine trading conditions. The sustained interest may reflect ongoing evaluations of market positioning as participants weigh the implications of recent performance data.